Bicyclo ring system having the six-membered hetero ring as one of the cyclos

Subclass of:

546 - Organic compounds -- part of the class 532-570 series

546000000 - ORGANIC COMPOUNDS (CLASS 532, SUBCLASS 1)

546000000 - HETEROCYCLIC CARBON COMPOUNDS CONTAINING A HETERO RING HAVING CHALCOGEN (I.E., OXYGEN, SULFUR, SELENIUM, OR TELLURIUM) OR NITROGEN AS THE ONLY RING HETERO ATOMS (Class 540, subclass 1)

546001000 - Hetero ring is six-membered consisting of one nitrogen and five carbons

546026000 - Polycyclo ring system having the six-membered hetero ring as one of the cyclos

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application number	Description	Number of patent applications / Date published
546113000	Plural ring hetero atoms in the bicyclo ring system	219
546152000	Quinolines (including hydrogenated)	209
546139000	Isoquinolines (including hydrogenated)	73
546133000	Quinuclidines (including unsaturated)	52
546124000	Tropanes (including nor and dehydro forms)	12
546183000	Chalcogen bonded directly to ring carbon of the bicyclo ring system	11
546138000	Quinolizines (including hydrogenated)	1
20090105480	PROCESS FOR THE PREPARATION OF A DPP-IV INHIBITOR - The present invention is concerned with an improved process for the preparation of pyrido[2,1-a]isoquinoline derivatives of formula I	04-23-2009

Entries
Document	Title	Date
20080214820	Enantiomers of 3-Heteroaryl-8H-8-Azabicyclo (3.2.1) Oct-2-Ene and their Use as Monoamine Neurotransmitter Re-Uptake Inhibitors - This invention relates to novel enantiomers useful as monoamine neurotransmitter re-uptake inhibitors.	09-04-2008
20090270626	STABLE BISTHIOL COMPOUNDS FOR RADIOIMAGING AND THERAPY - The invention provides compounds and methods for preparing radiopharmaceutical compounds useful as therapeutic and diagnostic agents.	10-29-2009
20100105914	CASPASE INHIBITORS AND USES THEREOF - The present invention provides a compound of formula I:	04-29-2010
20100113789	MEDICINAL COMPOSITION FOR PREVENTION OR TREATMENT OF PARASITIC PROTOZOAN INFECTION - The present invention is to provide a medicinal composition for preventing or treating parasitic protozoan infections, having a high selective toxicity against parasitic protozoan infection, and a superior preventive or treating effect. A medicinal composition for preventing or treating parasitic protozoan infections comprises a compound shown by the following general formula (1) as an active ingredient	05-06-2010
20100249416	CHEMICAL SYNTHESIS OF I-124BETA CIT IODINE-124 [2-BETA-CARBOMETHOXY-3BETA- (4. -IODOPHENYL) -TROPANE] FOR PET INVESTIGATIONS AND FOR RADIOTHERAPY - The present invention concerns a new molecule, I-124βCIT Iodine-124[2β-carbomethoxy-3β-(4-iodophenyl)-tropane] and its process of synthesis, for use in PET investigations.	09-30-2010
20110071298	Processes and Intermediates - The invention relates to processes and compounds useful for producing modified aspartic acid derivatives, such as aspartic acid aldehyde moieties. Aspartic acid derivatives are useful for preparing caspase inhibitors and/or prodrugs thereof.	03-24-2011
20110313165	QUINOLIZIDINE AND INDOLIZIDINE DERIVATIVES - The present invention relates to a compound of formula I-A or I-B	12-22-2011
20130345427	COLORANT COMPOUND DERIVED FROM GENIPA AMERICANA GENIPIN AND GLYCINE - The present invention provides colorant compounds and its molecular structural formulas and methods of isolation of the colorant compounds derived from a reaction of	12-26-2013
20140018540	CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS - The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.	01-16-2014
20150148541	NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS - Provided herein are novel and selective high affinity α3β4 nicotinic acetycholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the α3β4 nicotinic acetycholine receptor using the compounds and compositions disclosed herein.	05-28-2015